Source:PIB
Subject: Science and Technology (Biotechnology and Bioeconomy); Indian Economy (Growth and Industry)|Target exams: UPSC
Key points for Prelims: Bioeconomy, Biotechnology Research and Innovation Council (BRIC), Department of Biotechnology, Nature Index India, BioE3 policy, Biomanufacturing
Mains syllabus mapping
- General Studies Paper 3: Science and Technology: developments and applications in biotechnology; Indian economy: industrial growth and startups
- General Studies Paper 2: Government policies and institutions for science and technology; institutional restructuring and governance
Biotechnology for Economy, Environment and Employment (BioE3) Policy for Fostering High Performance Biomanufacturing: quick facts
- Cabinet approval
- Union Cabinet approved the BioE3 Policy on 24 August 2024
- Full name
- Biotechnology for Economy, Environment and Employment; policy for Fostering High Performance Biomanufacturing
- Thematic sectors
- Six sectors: bio-based chemicals, biopolymers and enzymes; smart proteins and functional foods; precision biotherapeutics; climate resilient agriculture; carbon capture and utilisation; marine and space research
Key facts for one-day exams
- BRIC stands for Biotechnology Research and Innovation Council.
- The 2030 Indian bioeconomy target is USD 300 billion.
- The 2047 Indian bioeconomy target is USD 1 trillion.
- Dr. Rajesh S. Gokhale is the Director General of BRIC.
- The D.E.S.I.G.N. for BioE3 Challenge received over 6,000 proposals.
Indian bioeconomy targets 2030 2047: why in the news?
Dr. Jitendra Singh announced the bioeconomy targets of USD 300 billion by 2030 and USD 1 trillion by 2047 at the fourth BRIC Society Annual General Meeting, where the council’s progress and future priorities were reviewed.
India’s bioeconomy is targeting USD 300 billion by 2030 and USD 1 trillion by 2047, Union Minister Dr. Jitendra Singh said on November 21 while chairing the fourth Annual General Meeting of the Biotechnology Research and Innovation Council (BRIC) Society in New Delhi. The Minister of State (Independent Charge) for Science & Technology and Earth Sciences said the integration of biotechnology research institutions under BRIC was among the first such initiatives in the government, and that the model has since inspired similar approaches in other organisations.
Dr. Jitendra Singh noted that India’s bioeconomy has grown from around USD 10 billion to over USD 195 billion. BRIC institutions ranked first among government institutions in health sciences and second in biological sciences in India for the second consecutive year, according to the Nature Index India. The Minister said scientific achievements must translate into technologies, products and solutions that make a tangible difference to people’s lives, and called for stronger engagement between scientists, entrepreneurs, investors and industry from the early stages of technology development.
The meeting reviewed BRIC’s institutional progress, scientific achievements, governance reforms, research collaborations and future priorities. Dr. Rajesh S. Gokhale, Secretary, Department of Biotechnology and Director General, BRIC, made a detailed presentation. The Minister welcomed initiatives such as the Entrepreneur-in-Residence programme and collaborations aimed at strengthening biomanufacturing, technology scale-up and commercialisation. He said India’s biotechnology startup ecosystem now comprises more than 11,000 startups.
The AGM also saw the launch of the BRIC Handbook of Memorandum of Association, Rules, Regulations and Bye-laws. Members were apprised of a proposal concerning the dissolution of existing societies of constituent autonomous institutions and their merger with BRIC as part of ongoing institutional restructuring. Referring to the D.E.S.I.G.N. for BioE3 Challenge, Dr. Jitendra Singh said it had received more than 6,000 proposals from school students and citizens. He stressed the importance of communicating scientific research in accessible formats and called for greater scale in innovation, industry participation and talent development to meet the 2030 and 2047 targets.
Key features and how it works
- Biomanufacturing & Bio-AI hubs and Biofoundry: these are set up to accelerate technology development and commercialisation.pmindia.gov.in
- Mulankur Bio-Enablers augment discovery and translation research across the six sectoral verticals. Bio-AI hubs enable discovery research across the sectors.birac.nic.in
- The policy enables institutions and industries to pursue innovation through Public-Private Partnerships and international collaborations. DBT implements the initiative with BIRAC, with DBT supporting academia and BIRAC supporting other entities.birac.nic.in
- Support covers innovation-driven R&D and entrepreneurship, and the policy is expected to expand a skilled workforce and job creation.pmindia.gov.in
Related Static GK and comparison
- Biotechnology Industry Research Assistance Council (BIRAC) is a Public Sector Enterprise set up by the Department of Biotechnology.birac.nic.in
- Department of Biotechnology (DBT): established in 1986, under the Ministry of Science and Technology; responsible for the development and commercialisation of modern biology and biotechnology in India.
- Mulankur Bio-Enablers: the BioE3 component that augments discovery and translation research across the sectoral verticals.birac.nic.in
Achievements
- India's bioeconomy has grown from around USD 10 billion to over USD 195 billion, and the D.E.S.I.G.N. for BioE3 Challenge received more than 6,000 proposals.PIB
- Shared biomanufacturing infrastructure gives start-ups and SMEs a route from lab-scale research to pilot production.
Challenges
- Moving research into products needs capital, mentorship, industry partnerships and clarity on market and regulatory pathways, which the Minister stressed.PIB
- Access to shared facilities may be uneven across regions, since hubs can be set up in existing, augmented or new facilities.
- Scientific output must be turned into commercially viable technology, which the Minister said should not stop at publications and patents.PIB
Way forward
- Stronger engagement between scientists, entrepreneurs, investors and industry from the early stages of technology development.PIB
- Scale-up through Public-Private Partnerships and international collaborations, as the policy envisages.birac.nic.in
- Develop talent and support research translation, including through initiatives such as the Entrepreneur-in-Residence programme.PIB
Connected to this news
Biotechnology for Economy, Environment and Employment (BioE3) Policy for Fostering High Performance Biomanufacturing
BioE3 is India's first biotechnology policy, approved by the Union Cabinet in August 2024, that promotes sustainable biomanufacturing through shared infrastructure for start-ups, SMEs, industry and academia.
Timeline
21 November 2026This story
Minister Jitendra Singh restated the USD 300 billion (2030) and USD 1 trillion (2047) bioeconomy targets at the BRIC Society AGM, noting the bioeconomy has grown past USD 195 billion.
24 August 2024
The Union Cabinet approved the BioE3 Policy for Fostering High Performance Biomanufacturing.
1986
The Department of Biotechnology was established.
Indian bioeconomy targets
| Target year | Target size |
|---|---|
| 2030 | USD 300 billion |
| 2047 | USD 1 trillion |
Key terms
- Bioeconomy:
- Economic activities that use biological resources, processes and knowledge to produce goods and services.
- Research translation:
- The process of turning research findings into practical applications, products or services.
- Biomanufacturing:
- The use of biological systems or processes to manufacture products.
Indian bioeconomy targets 2030 2047: why it matters for exams
Exams: UPSC
Syllabus: Science and Technology: Biotechnology and its applications; Economy: Innovation and industrial development
Common mistake: Examiners may present USD 1 trillion as the 2030 target; the target is USD 300 billion for 2030 and USD 1 trillion for 2047.
Mains practice questions
Question 1(GS-3 | 250 words | 15 marks)
Critically examine the potential of India's bioeconomy, with targets of USD 300 billion by 2030 and USD 1 trillion by 2047, as a driver of inclusive economic growth. What structural challenges must be addressed to convert scientific research into commercially viable products?
Answer outline
- Introduction: Open by noting that the bioeconomy has grown from around USD 10 billion to over USD 195 billion, showing the sector's momentum and the ambition behind the 2030 and 2047 targets announced at the BRIC AGM.
- Body:
- Potential: biotechnology across health, agriculture, industrial processes and biomanufacturing can create high-value jobs and export earnings, with more than 11,000 biotechnology startups indicating a vibrant entrepreneurial base.
- Institutional strength: BRIC institutions ranking first in health sciences and second in biological sciences in Nature Index India reflect research depth that can feed commercial pipelines.
- Translation gap: the Minister stressed that scientific achievements must become products that make a tangible difference; weak links between laboratories, industry and investors slow technology scale-up.
- Need for early industry engagement, scale-up infrastructure, talent development and biomanufacturing capacity, as reflected in the Entrepreneur-in-Residence programme and collaborations.
- Inclusiveness concerns: ensuring that gains reach rural and smaller enterprises, and that public research serves social needs beyond market returns.
- Conclusion: A balanced way forward combines sustained public funding, stronger academia-industry-investor linkages and inclusive access, so that the bioeconomy targets advance both growth and public welfare.
Question 2(GS-2 | 150 words | 10 marks)
Discuss the role of institutional restructuring and governance reforms, such as the merger of autonomous institutions into BRIC, in improving the effectiveness of India's science and technology research ecosystem.
Answer outline
- Introduction: Link the news to the AGM, where a proposal to dissolve existing societies of constituent autonomous institutions and merge them with BRIC was discussed as part of ongoing restructuring.
- Body:
- Rationale for consolidation: a single governance structure can reduce duplication, streamline decision-making and create a unified research vision across constituent institutions.
- Governance reforms: the launch of the BRIC Handbook of Memorandum of Association, Rules, Regulations and Bye-laws signals clearer, standardised rules for accountability.
- Collaboration and talent: integrated institutions can pool resources and expertise, and the model is reported to have inspired similar approaches elsewhere.
- Risks: loss of autonomy, resistance from existing institutions and the need for transparent transition processes.
- Conclusion: Restructuring can strengthen research effectiveness if it is paired with safeguards that preserve scientific autonomy and inclusive participation.
Stuck? Get it in one tap
The bioeconomy uses biological resources and knowledge to make products and provide services. BRIC brings research institutions together to share facilities and expertise. Its goals include helping discoveries become useful technologies and supporting India's long-term bioeconomy targets.
- Science and Technology: Biotechnology and its applications
- Economy: Innovation and industrial development
Related concepts: Bioeconomy, Research translation, Biomanufacturing
Practice questions
Pick an answer, then read the explanation.
- Q1Easy
Which department is associated with the Biotechnology Research and Innovation Council?
Explanation: The Department of Biotechnology is associated with BRIC, whose Director General is also the department's Secretary. The other departments are distinct government bodies.
- Q2Hard
Consider the following statements about BRIC and India's bioeconomy:
- 1. The bioeconomy target for 2030 is USD 1 trillion.
- 2. BRIC institutions share resources while retaining their scientific strengths.
- 3. More than 11,000 biotechnology startups form part of India's ecosystem.
Which of the statements given above is/are correct?
Explanation: Statement 1 is incorrect: USD 1 trillion is the 2047 target; the 2030 target is USD 300 billion. Statements 2 and 3 correctly describe BRIC's model and the size of the startup ecosystem.
- Q3Medium
Why does BRIC seek closer engagement between researchers, investors and industry during technology development?
Explanation: Capital, mentorship and industry partnerships can help take research from the laboratory to the market. BRIC's model instead promotes interdisciplinary collaboration and research aligned with societal needs.
Frequently asked questions
1. What are India's bioeconomy targets for 2030 and 2047?
The targets are USD 300 billion by 2030 and USD 1 trillion by 2047.
2. What is BRIC in biotechnology?
BRIC is the Biotechnology Research and Innovation Council, which brings biotechnology institutions together through collaborative research and shared resources.
3. How large is India's biotechnology startup ecosystem?
India's biotechnology startup ecosystem comprises more than 11,000 startups.
4. How many proposals did the D.E.S.I.G.N. for BioE3 Challenge receive?
The challenge received more than 6,000 proposals across school-student and citizen categories.
All sources
Original21 November 2026 · Read story


